Clinical trial
Pomalidomide for the Treatment of Bleeding in Hereditary Hemorrhagic Telangiectasia
NCT03910244 is registered in ClinicalTrials.gov with The Cleveland Clinic as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Pomalidomide for the Treatment of Bleeding in Hereditary Hemorrhagic Telangiectasia
- Lead sponsor
- The Cleveland Clinic
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- October 17, 2019
- Completion date
- September 8, 2023
- Enrollment
- 145 (actual)
- Sites
- 14
Conditions
As the registry lists them; a condition with its own page is linked.